Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases
Silje Watterdal Syversen, Kristin Kaasen Jørgensen, Guro Løvik Goll, et al.
JAMA (2021) Vol. 326, Iss. 23, pp. 2375-2375
Open Access | Times Cited: 116

Showing 51-75 of 116 citing articles:

Personalized Dosing of Infliximab in Patients With Inflammatory Bowel Disease Using a Bayesian Approach: A Next Step in Therapeutic Drug Monitoring
Devendra Desai, Alpa J. Dherai, Anne S. Strik, et al.
The Journal of Clinical Pharmacology (2022) Vol. 63, Iss. 4, pp. 480-489
Open Access | Times Cited: 11
HLA‐DQ2 is associated with anti‐drug antibody formation to infliximab in patients with immune‐mediated inflammatory diseases
Marthe Kirkesæther Brun, K. H. Bjørlykke, Marte K. Viken, et al.
Journal of Internal Medicine (2023) Vol. 293, Iss. 5, pp. 648-655
Open Access | Times Cited: 6
Comparative Evaluation of Four Commercially Available Immunoassays for Therapeutic Drug Monitoring of Infliximab and Adalimumab
F. Rissel, Yoann Cazaubon, Syrine Saffar, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 12, pp. 10379-10379
Open Access | Times Cited: 6
Relationship Between Serum Ustekinumab Trough Concentration and Clinical and Biochemical Disease Activity: A Real-World Study in Adult Patients with Crohn’s Disease
Khue M. Nguyen, Vandita Y. Mattoo, Sara Vogrin, et al.
European Journal of Drug Metabolism and Pharmacokinetics (2023) Vol. 48, Iss. 3, pp. 271-279
Closed Access | Times Cited: 5
Efficacy and safety of proactive drug monitoring in inflammatory bowel disease treated with anti-TNF agents: A systematic review and meta-analysis
Noemí Manceñido, Blanca Novella Arribas, Gustavo Mora Navarro, et al.
Digestive and Liver Disease (2023) Vol. 56, Iss. 3, pp. 421-428
Closed Access | Times Cited: 5
A Review of Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Receiving Combination Therapy
Sanket Patel, Andrés Yarur
Journal of Clinical Medicine (2023) Vol. 12, Iss. 20, pp. 6577-6577
Open Access | Times Cited: 5
Therapeutic drug monitoring of monoclonal antibodies in chronic inflammatory diseases: A snapshot of laboratories and applications across Europe
Silje Skrede, Nataša Bogavac‐Stanojević, Erwin Dreesen, et al.
Basic & Clinical Pharmacology & Toxicology (2024) Vol. 134, Iss. 4, pp. 556-560
Open Access | Times Cited: 1
Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Moderate-to-Severe Psoriasis
Jonathan D. Greenzaid, Steven R. Feldman
Clinical Pharmacokinetics (2024)
Closed Access | Times Cited: 1
Tocilizumab Dose Tapering Based on a Model-Based Algorithm is Feasible in Clinical Practice: A Short Communication
Femke Hooijberg, Zohra Layegh, Maureen Leeuw, et al.
Therapeutic Drug Monitoring (2024) Vol. 46, Iss. 3, pp. 410-414
Closed Access | Times Cited: 1
Is tumor necrosis factor-α monoclonal therapy with proactive therapeutic drug monitoring optimized for inflammatory bowel disease? Network meta-analysis
Fang-Yuan Zheng, Kaisi Yang, Wen-Cheng Min, et al.
World Journal of Gastrointestinal Surgery (2024) Vol. 16, Iss. 2, pp. 571-584
Open Access | Times Cited: 1
Overcoming provider barriers to therapeutic drug monitoring of tumour necrosis factor inhibitors for rheumatoid arthritis: a qualitative analysis
Sean P. Gavan, Katherine Payne, Anne Barton
Rheumatology Advances in Practice (2024) Vol. 8, Iss. 2
Open Access | Times Cited: 1
Therapeutic drug monitoring, liquid biopsies or pharmacogenomics for prediction of human drug metabolism and response
Magnus Ingelman‐Sundberg, Espen Molden
British Journal of Clinical Pharmacology (2024)
Open Access | Times Cited: 1
Evaluation of intra‐ and inter‐individual variations in plasma belimumab concentrations in adult patients with systemic lupus erythematosus
Chisato Yoshijima, Yosuke Suzuki, Ryota Tanaka, et al.
Pharmacology Research & Perspectives (2024) Vol. 12, Iss. 4
Open Access | Times Cited: 1
Autoimmune Diseases and Cardiovascular Risk: Mendelian Randomization Analysis for the Impact of 19 Autoimmune Diseases on 14 Cardiovascular Conditions
Yi Bao, Luo Gu, Jiayi Chen, et al.
Journal of Translational Autoimmunity (2024) Vol. 9, pp. 100259-100259
Open Access | Times Cited: 1
A Systematic Review on the Interest of Drug-tolerant Assay in the Monitoring of Inflammatory Bowel Disease
Mathilde Barrau, Manon Duprat, Pauline Veyrard, et al.
Journal of Crohn s and Colitis (2022) Vol. 17, Iss. 4, pp. 633-643
Closed Access | Times Cited: 8
Evidence on the therapeutic role of thiolutin in imiquimod‐induced psoriasis‐like skin inflammation in mice
Aixue Wang, Xixing Ma, Feng Wei, et al.
Immunity Inflammation and Disease (2023) Vol. 11, Iss. 7
Open Access | Times Cited: 4
Autoantibodies from patients with kidney allograft vasculopathy stimulate a proinflammatory switch in endothelial cells and monocytes mediated via GPCR-directed PAR1-TNF-α signaling
Guido Moll, Christian Luecht, Michael Adu Gyamfi, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 4
Challenges in IBD Research 2024: Pragmatic Clinical Research
Jessica R. Allegretti, Liliana Bordeianou, Oriana M. Damas, et al.
Inflammatory Bowel Diseases (2024) Vol. 30, Iss. Supplement_2, pp. S55-S66
Open Access | Times Cited: 1
Different infliximab induction dosing regimens do not affect remission rates up to 1 year in children with Crohn's disease
Tal Marshanski, Eliana Fanous, Noa Tal, et al.
Journal of Pediatric Gastroenterology and Nutrition (2024) Vol. 79, Iss. 3, pp. 564-572
Closed Access | Times Cited: 1
Proactive therapeutic drug monitoring of biologic drugs in patients with inflammatory bowel disease, inflammatory arthritis, and psoriasis: systematic review and meta-analysis
Dena Zeraatkar, Tyler Pitre, Sarah Kirsh, et al.
BMJ Medicine (2024) Vol. 3, Iss. 1, pp. e000998-e000998
Open Access | Times Cited: 1
A guideline on biomarkers in the diagnosis and evaluation in axial spondyloarthritis
Dong Liu, Ya Xie, Liudan Tu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Pediatric Extrapolation of Adult Efficacy to Children Is Critical for Efficient and Successful Drug Development
Andrew E. Mulberg, Laurie S. Conklin, Nicholas M. Croft, et al.
Gastroenterology (2022) Vol. 163, Iss. 1, pp. 77-83
Open Access | Times Cited: 7
Reduced prescription of TNF-inhibitors in chronic arthritis based on therapeutic drug monitoring: A randomized controlled trial
Mogens Pfeiffer‐Jensen, Donghua Liao, Ulrik Tarp, et al.
Scandinavian Journal of Rheumatology (2022) Vol. 52, Iss. 5, pp. 468-480
Open Access | Times Cited: 7
Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia
K. H. Bjørlykke, Jørgen Jahnsen, Jørn Brynskov, et al.
Scandinavian Journal of Gastroenterology (2022) Vol. 58, Iss. 1, pp. 25-33
Open Access | Times Cited: 6
Current Role of Monoclonal Antibody Therapy in Pediatric IBD: A Special Focus on Therapeutic Drug Monitoring and Treat-to-Target Strategies
M. Classen, André Hoerning
Children (2023) Vol. 10, Iss. 4, pp. 634-634
Open Access | Times Cited: 3

Scroll to top